Does the media prefer MCRB or PLX?

In the previous week, Protalix BioTherapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for Protalix BioTherapeutics and 3 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat Protalix BioTherapeutics' score of 0.11 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Protalix BioTherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NBP or MCRB more profitable?

I-Mab has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. I-Mab's return on equity of 0.00% beat Seres Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets I-Mab N/A N/A N/A Seres Therapeutics -1,192.94% -114.82% -34.15%

Does the media favor NBP or MCRB?

In the previous week, Seres Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.94 beat Seres Therapeutics' score of 0.36 indicating that I-Mab is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment I-Mab 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer VYGR or MCRB?

In the previous week, Voyager Therapeutics had 14 more articles in the media than Seres Therapeutics. MarketBeat recorded 17 mentions for Voyager Therapeutics and 3 mentions for Seres Therapeutics. Voyager Therapeutics' average media sentiment score of 0.94 beat Seres Therapeutics' score of 0.36 indicating that Voyager Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Voyager Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MCRB or MDWD?

In the previous week, MediWound had 7 more articles in the media than Seres Therapeutics. MarketBeat recorded 10 mentions for MediWound and 3 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat MediWound's score of -0.26 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 0 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor MCRB or PRQR?

In the previous week, ProQR Therapeutics had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for ProQR Therapeutics and 3 mentions for Seres Therapeutics. ProQR Therapeutics' average media sentiment score of 1.29 beat Seres Therapeutics' score of 0.36 indicating that ProQR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Seres Therapeutics (MCRB) Competitors

$4.54 +0.06 (+1.34%)

Closing price 04:00 PM Eastern

Extended Trading

$4.50 -0.04 (-0.99%)

As of 07:34 PM Eastern

Compare

MCRB vs. PLX, NBP, VYGR, MDWD, and PRQR

Should you buy Seres Therapeutics stock or one of its competitors? Seres Therapeutics's main competitors and comparable companies include Protalix BioTherapeutics (PLX), I-Mab (NBP), Voyager Therapeutics (VYGR), MediWound (MDWD), and ProQR Therapeutics (PRQR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Seres Therapeutics compare to Protalix BioTherapeutics?

Seres Therapeutics (NASDAQ:MCRB) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, media sentiment, analyst recommendations, earnings and institutional ownership.

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Protalix BioTherapeutics had 3 more articles in the media than Seres Therapeutics. MarketBeat recorded 6 mentions for Protalix BioTherapeutics and 3 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat Protalix BioTherapeutics' score of 0.11 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Protalix BioTherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protalix BioTherapeutics has a net margin of -21.03% compared to Seres Therapeutics' net margin of -1,192.94%. Protalix BioTherapeutics' return on equity of -30.89% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 274.45%. Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 440.54%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Seres Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Protalix BioTherapeutics has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market.

Protalix BioTherapeutics has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A
Protalix BioTherapeutics	$76.38M	2.34	$8.31M	$0.18	12.33

Summary

Protalix BioTherapeutics beats Seres Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to I-Mab?

I-Mab (NASDAQ:NBP) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends, earnings and media sentiment.

Seres Therapeutics has lower revenue, but higher earnings than I-Mab. I-Mab is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
I-Mab	$3.89M	58.27	-$46.27M	-$0.36	N/A
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A

I-Mab has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market.

In the previous week, Seres Therapeutics had 1 more articles in the media than I-Mab. MarketBeat recorded 3 mentions for Seres Therapeutics and 2 mentions for I-Mab. I-Mab's average media sentiment score of 0.94 beat Seres Therapeutics' score of 0.36 indicating that I-Mab is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
I-Mab	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

38.4% of I-Mab shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 22.1% of I-Mab shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

I-Mab has a net margin of 0.00% compared to Seres Therapeutics' net margin of -1,192.94%. I-Mab's return on equity of 0.00% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
I-Mab	N/A	N/A	N/A
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

I-Mab presently has a consensus target price of $9.00, indicating a potential upside of 359.18%. Seres Therapeutics has a consensus target price of $17.00, indicating a potential upside of 274.45%. Given I-Mab's higher probable upside, equities analysts plainly believe I-Mab is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
I-Mab	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

I-Mab beats Seres Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to Voyager Therapeutics?

Voyager Therapeutics (NASDAQ:VYGR) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, media sentiment, risk, profitability, valuation and earnings.

48.0% of Voyager Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 12.7% of Voyager Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Seres Therapeutics has lower revenue, but higher earnings than Voyager Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Voyager Therapeutics	$34.46M	5.85	-$119.72M	-$1.80	N/A
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A

In the previous week, Voyager Therapeutics had 14 more articles in the media than Seres Therapeutics. MarketBeat recorded 17 mentions for Voyager Therapeutics and 3 mentions for Seres Therapeutics. Voyager Therapeutics' average media sentiment score of 0.94 beat Seres Therapeutics' score of 0.36 indicating that Voyager Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Voyager Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Voyager Therapeutics has a beta of 1.31, meaning that its stock price is 31% more volatile than the broader market. Comparatively, Seres Therapeutics has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

Voyager Therapeutics presently has a consensus target price of $16.50, suggesting a potential upside of 404.59%. Seres Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 274.45%. Given Voyager Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Voyager Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Voyager Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Voyager Therapeutics has a net margin of -312.63% compared to Seres Therapeutics' net margin of -1,192.94%. Voyager Therapeutics' return on equity of -57.92% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Voyager Therapeutics	-312.63%	-57.92%	-45.00%
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%

Summary

Voyager Therapeutics beats Seres Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Seres Therapeutics compare to MediWound?

Seres Therapeutics (NASDAQ:MCRB) and MediWound (NASDAQ:MDWD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

In the previous week, MediWound had 7 more articles in the media than Seres Therapeutics. MarketBeat recorded 10 mentions for MediWound and 3 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.36 beat MediWound's score of -0.26 indicating that Seres Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Seres Therapeutics has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, MediWound has a beta of 0.15, indicating that its stock price is 85% less volatile than the broader market.

Seres Therapeutics currently has a consensus target price of $17.00, suggesting a potential upside of 274.45%. MediWound has a consensus target price of $33.00, suggesting a potential upside of 143.36%. Given Seres Therapeutics' higher probable upside, equities research analysts clearly believe Seres Therapeutics is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

MediWound has a net margin of -170.10% compared to Seres Therapeutics' net margin of -1,192.94%. MediWound's return on equity of -44.77% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
MediWound	-170.10%	-44.77%	-23.23%

Seres Therapeutics has higher earnings, but lower revenue than MediWound. MediWound is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A
MediWound	$16.96M	10.27	-$23.88M	-$2.26	N/A

59.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 5.2% of Seres Therapeutics shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Seres Therapeutics and MediWound tied by winning 7 of the 14 factors compared between the two stocks.

How does Seres Therapeutics compare to ProQR Therapeutics?

Seres Therapeutics (NASDAQ:MCRB) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership, media sentiment and dividends.

Seres Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market.

In the previous week, ProQR Therapeutics had 2 more articles in the media than Seres Therapeutics. MarketBeat recorded 5 mentions for ProQR Therapeutics and 3 mentions for Seres Therapeutics. ProQR Therapeutics' average media sentiment score of 1.29 beat Seres Therapeutics' score of 0.36 indicating that ProQR Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Seres Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics has a net margin of -331.33% compared to Seres Therapeutics' net margin of -1,192.94%. ProQR Therapeutics' return on equity of -84.87% beat Seres Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Seres Therapeutics	-1,192.94%	-114.82%	-34.15%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 5.2% of Seres Therapeutics shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Seres Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Seres Therapeutics	$790K	57.12	$5.70M	-$2.43	N/A
ProQR Therapeutics	$17.99M	11.24	-$47.73M	-$0.50	N/A

Seres Therapeutics currently has a consensus price target of $17.00, indicating a potential upside of 274.45%. ProQR Therapeutics has a consensus price target of $7.33, indicating a potential upside of 281.94%. Given ProQR Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Seres Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Seres Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

ProQR Therapeutics beats Seres Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Seres Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MCRB vs. The Competition

Export

Metric	Seres Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$44.54M	$3.74B	$7.06B	$13.10B
Dividend Yield	N/A	3.69%	2.57%	10.45%
P/E Ratio	-1.87	10.67	269.06	25.28
Price / Sales	57.12	1,294.08	602.43	91.76
Price / Cash	4.12	102.88	70.48	50.90
Price / Book	1.31	16.78	12.91	6.24
Net Income	$5.70M	-$13.32M	$3.45B	$347.60M
7 Day Performance	-6.78%	1.74%	1.12%	1.07%
1 Month Performance	-14.98%	1.60%	1.79%	1.03%
1 Year Performance	-73.07%	56.43%	67.69%	20.77%

Seres Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MCRB Seres Therapeutics	2.5616 of 5 stars	$4.54 +1.3%	$17.00 +274.4%	-71.9%	$44.54M	$790K	N/A	330	Analyst Downgrade
PLX Protalix BioTherapeutics	2.9274 of 5 stars	$2.32 -2.1%	$12.00 +417.2%	+46.6%	$186.93M	$76.38M	N/A	200	News Coverage
NBP I-Mab	2.2711 of 5 stars	$1.61 +0.6%	$9.00 +459.0%	N/A	$185.04M	$3.89M	N/A	380	News Coverage
VYGR Voyager Therapeutics	3.2836 of 5 stars	$3.00 -1.0%	$16.50 +450.0%	-11.8%	$183.08M	$40.37M	N/A	100	Analyst Revision
MDWD MediWound	3.048 of 5 stars	$14.22 +0.7%	$34.00 +139.1%	-27.8%	$181.47M	$14.48M	N/A	80	News Coverage Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MCRB) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Seres Therapeutics (MCRB) Competitors

MCRB vs. PLX, NBP, VYGR, MDWD, and PRQR

How does Seres Therapeutics compare to Protalix BioTherapeutics?

Summary

How does Seres Therapeutics compare to I-Mab?

Summary

How does Seres Therapeutics compare to Voyager Therapeutics?

Summary

How does Seres Therapeutics compare to MediWound?

Summary

How does Seres Therapeutics compare to ProQR Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Seres Therapeutics (MCRB) Competitors

MCRB vs. PLX, NBP, VYGR, MDWD, and PRQR

How does Seres Therapeutics compare to Protalix BioTherapeutics?

Do institutionals and insiders hold more shares of MCRB or PLX?

Does the media prefer MCRB or PLX?

Is MCRB or PLX more profitable?

Do analysts recommend MCRB or PLX?

Which has more volatility & risk, MCRB or PLX?

Which has better earnings and valuation, MCRB or PLX?

Summary

How does Seres Therapeutics compare to I-Mab?

Which has preferable earnings and valuation, NBP or MCRB?

Which has more volatility & risk, NBP or MCRB?

Does the media favor NBP or MCRB?

Do institutionals and insiders have more ownership in NBP or MCRB?

Is NBP or MCRB more profitable?

Do analysts recommend NBP or MCRB?

Summary

How does Seres Therapeutics compare to Voyager Therapeutics?

Do institutionals & insiders have more ownership in VYGR or MCRB?

Which has higher earnings & valuation, VYGR or MCRB?

Does the media prefer VYGR or MCRB?

Which has more risk and volatility, VYGR or MCRB?

Do analysts prefer VYGR or MCRB?

Is VYGR or MCRB more profitable?

Summary

How does Seres Therapeutics compare to MediWound?

Does the media favor MCRB or MDWD?

Which has more volatility & risk, MCRB or MDWD?

Do analysts rate MCRB or MDWD?

Is MCRB or MDWD more profitable?

Which has preferable valuation & earnings, MCRB or MDWD?

Do institutionals & insiders hold more shares of MCRB or MDWD?

Summary

How does Seres Therapeutics compare to ProQR Therapeutics?

Which has more volatility & risk, MCRB or PRQR?

Does the media favor MCRB or PRQR?

Is MCRB or PRQR more profitable?

Do insiders and institutionals believe in MCRB or PRQR?

Which has stronger valuation and earnings, MCRB or PRQR?

Do analysts prefer MCRB or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MCRB vs. The Competition

Seres Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools